- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.12. | Virax Biolabs Unveils $5 Million Private Placement | 3 | RTTNews | ||
| 04.12. | Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally | 1 | Benzinga.com | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 02.12. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.11. | Virax BioLabs Group Limited: Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes | 199 | PR Newswire | LONDON, Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection... ► Artikel lesen | |
| 01.09. | Virax Biolabs Collaborating With Emory University On Clinical Studies | 1 | pulse2.com | ||
| 27.08. | Virax Biolabs (VRAX) Falls 18% on Lack of Leads | 1 | Insider Monkey | ||
| 26.08. | Virax Biolabs partners with Emory for long COVID diagnostic studies | 1 | Investing.com | ||
| 26.08. | Virax Biolabs startet mit Emory University Studien zur Long-COVID-Diagnostik | 1 | Investing.com Deutsch | ||
| 26.08. | Virax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | 189 | PR Newswire | LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune... ► Artikel lesen | |
| 26.08. | EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies | 2 | Benzinga.com | ||
| 30.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 29.07. | Virax Biolabs appoints Iain Miller as independent director | 1 | Investing.com | ||
| 18.07. | Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule | 5 | Seeking Alpha | ||
| 18.07. | Virax Biolabs receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
| 18.07. | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 208 | PR Newswire |
LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen | |
| 02.07. | Virax Biolabs Group Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 220 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 604 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 450 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,25 | +0,25 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| EVOTEC | 5,212 | +1,32 % | EVOTEC SE wankt - jetzt zählt jede Sekunde! | ||
| ASEP MEDICAL | 0,164 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,850 | -0,72 % | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment | Collaboration reduces time in fermenting complex bacterial strains, enabling continued focus on next-gen biological crop solutions.
BOSTON and PLANO, Texas, Dec.... ► Artikel lesen | |
| AGIOS | 21,200 | +0,95 % | Agios Pharmaceuticals, Inc.: Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia | CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients... ► Artikel lesen | |
| GENPREX | 2,120 | -2,30 % | Genprex, Inc.: Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer | Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa® Gene Therapy with Tagrisso®
AUSTIN, Texas, Nov. 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex"... ► Artikel lesen | |
| PALISADE BIO | 1,835 | +9,88 % | Palisade Bio, Inc.: Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development | Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025... ► Artikel lesen | |
| GEOVAX LABS | 0,158 | -34,07 % | GeoVax Labs, Inc. - S-1, General form for registration of securities | ||
| ANNOVIS BIO | 3,075 | -1,60 % | Annovis Bio Inc.: Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients | ||
| SAGIMET BIOSCIENCES | 5,350 | 0,00 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination | The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination... ► Artikel lesen | |
| HUMACYTE | 1,115 | +0,45 % | Humacyte announces credit facility of $77.5M with Avenue Capital | ||
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock |
VIRAX BIOLABS GROUP LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,007 (+1,74 %) liegt der Kurs bei 0,397 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.